

Our current concept of HDL remodeling in vivo in humans, presented in **Fig. 7**, is based on data generated in various genetic states associated with alterations in HDL metabolism (ABCA1, LCAT, and CETP deficiency). We are in the process of examining HDL subpopulations in other genetic disorders as well [apoA-I deficiency, apoE deficiency, abetalipoproteinemia, lipoprotein lipase (LPL) deficiency, and hepatic lipase (HL) deficiency]. On the basis of our observations, we describe the following steps in HDL metabolism.

#### Step 1: synthesis

ApoA-I is synthesized in the liver and small intestine, and two molecules of apoA-I form a belted structure around ~16 molecules of phospholipids to form discoidal pre $\beta$ -1 HDL in the interstitial or plasma compartment.

#### Step 2: cellular cholesterol efflux

Pre $\beta$ -1 particles pick up FC and more phospholipids from cells via the ABCA1 pathway and are transformed into small, lipid-poor, discoidal LpA-I  $\alpha$ -4 HDL particles.

#### Step 3: cholesterol esterification

LCAT esterifies FC on the surface of HDL into cholesteryl esters, which move into the core with an increase in HDL particle size.

#### Step 4: TG hydrolysis

LPL hydrolyzes TGs in TG-rich lipoprotein (TRL), resulting in surface components (phospholipids, FC, and apolipoproteins) available and necessary for HDL particle size increase.

The concerted actions of ABCA1, LCAT, and LPL continuously increase HDL particle size (steps 2–4).

#### Step 5: cholesteryl ester exchange (CETP cycle)

With CETP-mediated exchange of core cholesteryl esters for TG between large HDL particles and TRL, differentiated  $\alpha$ - and pre $\alpha$ -migrating HDL particles form; these contain apoA-I with apoA-II, or apoA-I without apoA-II, or apoE only. CETP can also exchange cholesteryl esters for TG among HDL particles and, as a result, a substantial amount of pre $\beta$ -1 forms.

#### Step 6: phospholipid hydrolysis

HL, endothelial lipase (EL), and secretory phospholipase A2 (sPLA2) hydrolyze TG and phospholipids on HDL, resulting in size reduction of large  $\alpha$ -1 into  $\alpha$ -2 HDL (HL), or disintegration of all larger HDL particles into  $\alpha$ -4 and pre $\beta$ -1 (EL), or pre $\beta$ -1 and free apoA-I (sPLA2).

#### Step 7: hepatic cholesteryl ester uptake (SR-BI cycle)


Cholesteryl esters on  $\alpha$ -2 and  $\alpha$ -1 HDL particles are selectively transported from HDL particles to the liver via SR-BI for ultimate excretion of cholesterol into the bile, resulting in recycling of apolipoproteins, phospholipids, and FC from these larger HDL particles to small  $\alpha$ -4 HDL.

The concerted actions of CETP, SR-BI, and lipases decrease HDL particle size (steps 5–7).

#### Step 8: apolipoprotein catabolism

Clearance of small, lipid-poor apoA-I particles: the final step in HDL particle metabolism is the uptake of whole HDL particles by the liver and cubulin/megalin-mediated clearance of free apoA-I and pre $\beta$ -1 HDL in the kidney.

Based on the observations presented here, our data are consistent with the concept that LCAT plays a crucial role in the maturation of HDL particles (steps 2–4). ■



**Fig. 7.** Current concept of HDL remodeling in humans in vivo. Abbreviations not used in the text: phospholipids (PL), cholesteryl ester (CE).

This study was supported by Grant HL-64738 from the National Institutes of Health/National Heart, Lung, and Blood Institute (B.F.A.), USDA Grant 53-1950-5-003 (E.J.S.), Telethon-Italy Grant GGP02264 (L.C.), Fondazione Cariplo Grant 2003-1753 (G.F.), and Grant PRIN2005 from the Italian Ministry of University (L.C., G.F.). The authors are indebted to Drs. M. Arca, S. Bertolini, G. Bittolo Bon, G. Boscutti, G. Busnach, G. Frascà, L. Gesualdo, G. Lupattelli, I. Rabbone, G. Ruotolo, T. Sampietro, and A. Sessa for the identification of the Italian LCAT-deficient families.

## REFERENCES

- McLean, J., C. Fielding, D. Drayna, H. Dieplinger, B. Baer, W. Kohr, W. Henzel, and R. Lawn. 1986. Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. *Proc. Natl. Acad. Sci. USA*. **83**: 2335–2339.
- Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. *J. Lipid Res.* **36**: 211–228.
- Czarnecka, H., and S. Yokoyama. 1996. Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange. *J. Biol. Chem.* **266**: 2023–2028.
- Jonas, A., A. von Eckardstein, K. E. Kezdy, A. Steinmetz, and G. Assmann. 1991. Structural and functional properties of reconstituted high density lipoprotein discs prepared with six apolipoprotein A-I variants. *J. Lipid Res.* **32**: 97–106.
- Steinmetz, A., H. Kaffarnik, and G. Utermann. 1985. Activation of phosphatidylcholine-sterol acyltransferase by human apolipoprotein E isoforms. *Eur. J. Biochem.* **152**: 747–751.
- Kuivenhoven, J. A., H. Pritchard, J. Hill, J. Frohlich, G. Assmann, and J. Kastelein. 1997. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. *J. Lipid Res.* **38**: 191–205.
- Santamarina-Fojo, S., J. M. Hoeg, G. Assmann, and H. B. Brewer, Jr. 2001. Lecithin cholesterol acyltransferase deficiency and fish eye disease. In *The Metabolic and Molecular Bases of Inherited Disease*. C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, editors. McGraw-Hill, New York. 2817–2834.
- Gordon, D. J., and B. M. Rifkind. 1989. High-density lipoprotein—the clinical implications of recent studies. *N. Engl. J. Med.* **321**: 1311–1316.
- Funke, H., A. von Eckardstein, P. H. Pritchard, J. J. Albers, J. J. Kastelein, C. Droste, and G. Assmann. 1991. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. *Proc. Natl. Acad. Sci. USA*. **88**: 4855–4859.
- Brousseau, M. E., S. Santamarina-Fojo, B. L. Vaisman, D. Applebaum-Bowden, A. M. Berard, G. D. Talley, H. B. Brewer, Jr., and J. M. Hoeg. 1997. Overexpression of human lecithin:cholesterol acyltransferase in cholesterol-fed rabbits: LDL metabolism and HDL metabolism are affected in a gene dose-dependent manner. *J. Lipid Res.* **38**: 2537–2547.
- Berard, A. M., B. Foger, A. Remaley, R. Shamburek, B. L. Vaisman, G. Talley, B. Paigen, R. F. Hoyt, Jr., S. Marcovina, H. B. Brewer, Jr., et al. 1997. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. *Nat. Med.* **3**: 744–749.
- Foger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, et al. 1999. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. *J. Biol. Chem.* **274**: 36912–36920.
- Asztalos, B. F., M. de la Llera-Moya, G. E. Dallal, K. V. Horvath, E. J. Schaefer, and G. H. Rothblat. 2005. Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux. *J. Lipid Res.* **46**: 2246–2253.
- Calabresi, L., L. Pisciotto, A. Costantin, I. Frigerio, I. Eberini, P. Alessandrini, M. Arca, G. B. Bon, G. Boscutti, G. Busnach, et al. 2005. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. *Arterioscler. Thromb. Vasc. Biol.* **25**: 1972–1978.
- Asztalos, B. F., M. Lefevre, T. A. Foster, R. Tulley, M. Windhauser, L. Wong, and P. S. Roheim. 1997. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. *Arterioscler. Thromb. Vasc. Biol.* **17**: 1885–1893.
- Asztalos, B. F., M. E. Brousseau, J. R. McNamara, K. V. Horvath, P. S. Roheim, and E. J. Schaefer. 2001. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. *Atherosclerosis*. **156**: 217–225.
- Asztalos, B. F., K. V. Horvath, K. Kajinami, C. Nartsupha, C. E. Cox, M. Batista, E. J. Schaefer, A. Inazu, and H. Mabuchi. 2004. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. *J. Lipid Res.* **45**: 448–455.
- Rader, D. J., K. Ikewaki, N. Duverger, H. Schmidt, H. Pritchard, J. Frohlich, M. Clerc, M. F. Dumon, T. Fairwell, L. Zech, et al. 1994. Markedly accelerated catabolism of apolipoprotein A-II (apoA-II) and high density lipoproteins containing apoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. *J. Clin. Invest.* **93**: 321–330.

# Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients

Shizuya Yamashita, Ken-ichi Hirano, Takahiro Kuwasako,  
Mohamed Janabi, Yumiko Toyama, Masato Ishigami  
and Naohiko Sakai

*Department of Internal Medicine and Molecular Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan*

## Abstract

Oxidized low density lipoprotein (LDL) (Ox-LDL) plays an important role in the pathogenesis of atherosclerosis. Oxidized LDL is taken up by macrophages via scavenger receptors. CD36 is an 88 kDa glycoprotein expressed on platelets, monocyte-macrophages, microvascular endothelial cells, adipose tissue, skeletal muscles and heart. We found patients with CD36 deficiency and identified several mutations in the CD36 gene. We also reported that CD36-deficient macrophages showed a 50% reduction in the binding of Ox-LDL, suggesting that CD36 is one of the major receptors for Ox-LDL. CD36 was expressed on macrophages in the atherosclerotic lesions of human aorta and coronary arteries especially on foamed macrophages. The distribution of CD36 expression was slightly different from that of scavenger receptor class A types I and II. The expression of CD36 on macrophages was up-regulated by Ox-LDL and down-regulated by interferon  $\gamma$ . Since CD36 is a transporter of long-chain fatty acids (LCFA), CD36-deficient patients showed a defect in the uptake of an LCFA analog, BMIPP, by the heart. Furthermore, the secretion of IL-1 $\beta$  and TNF- $\alpha$  from monocyte-derived macrophages induced by Ox-LDL was markedly reduced and the activation of NF- $\kappa$ B was attenuated in CD36-deficient subjects compared with controls, suggesting that CD36-mediated signaling is also impaired in CD36 deficiency.

To elucidate the roles of CD36 *in vivo*, we characterized the clinical profile of CD36-deficient patients. Most of them were accompanied by hyperlipidemia (mainly hypertriglyceridemia), increased remnant lipoproteins and mild elevation of fasting plasma glucose level and blood pressure. Glucose clamp technique revealed mean whole body glucose uptake was reduced in CD36-deficient patients, indicating the presence of insulin resistance. The frequency of CD36 deficiency was higher in patients with coronary heart disease (CHD) than in control subjects. Taken together, CD36 deficiency is accompanied by (1) hyperlipidemia and increased remnant lipoproteins, (2) impaired glucose metabolism based upon insulin resistance, and (3) mild hypertension, and comprises one of the genetic backgrounds of the metabolic syndrome, leading to the development of CHD.

**Key words:** scavenger receptor, CD36 deficiency, atherosclerosis, fatty acid transporter

## Introduction

Ox-LDL has been shown to play a crucial role in the pathogenesis of atherosclerosis. Modified lipoproteins such as

Ox-LDL are taken up by scavenger receptors expressed on macrophages. A number of molecules including scavenger receptor class A have been identified so far. CD36 is an 88 kDa glycoprotein belonging to class B scavenger

receptors [1]. Cells overexpressing CD36 bound and took up Ox-LDL [2], whereas CD36-deficient macrophages were resistant to foam cell formation *in vitro* [3]. Thus, CD36 could be one of the major receptors for Ox-LDL in humans. Furthermore, the expression of CD36 gene was up-regulated by its own ligand, Ox-LDL, while it was down-regulated by interferon  $\gamma$  [4, 5]. CD36 was abundantly expressed on the foam cells of human atherosclerotic plaques [6]. The distribution and localization of CD36 in the lesions were different from those of scavenger receptor class A [7]. CD36 is also expressed in multiple organs such as heart, skeletal muscles, and adipose tissues other than macrophages and platelets. Many *in vitro* experimental studies showed that CD36 could bind multiple ligands such as LCFA, thrombospondin-1, collagen, malaria-infected erythrocytes, and native lipoproteins [8]. These results indicated that CD36 may play some roles other than scavenger receptor for Ox-LDL. We found patients with genetic deficiency of CD36 in 1990 from those with refractoriness to platelet transfusion [9]. We analyzed the molecular bases and identified mutations in the CD36 gene [10, 11]. The aim of the present study was to investigate the phenotypic expression and pathophysiology of human CD36 deficiency.

## Results

### Characterization of macrophages from CD36-deficient patients

As mentioned earlier, CD36-deficient macrophages obtained from the patients showed an approximately 50% reduced binding and uptake of Ox-LDL, leading to the resistance to the foam cell formation *in vitro* [3]. CD36 could bind with Ox-LDL in transfected HEK293 cells [2]. As far as we know, CD36 deficiency is the only genetic deficiency state among scavenger receptors. Furthermore, CD36 was shown to be a receptor to collagen. We demonstrated that the CD36-deficient macrophages presented with a reduced binding to the collagen-coated culture dishes [12].

Ox-LDL and bacterial lipopolysaccharides (LPS) stimulate macrophages to secrete several proinflammatory cytokines, such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and interleukin  $1\beta$  (IL- $1\beta$ ). These reactions are regulated by a nuclear receptor, nuclear factor kappa B (NF- $\kappa$ B). We reported that the upregulation of inflammatory cytokine expression by Ox-LDL and activation of NF- $\kappa$ B were markedly reduced in CD36-deficient macrophages, whereas LPS-induced upregulation of NF- $\kappa$ B and cytokine expression were conserved [13].

### Clinical features of patients with CD36 deficiency

#### *Abnormal metabolic dynamics of LCFA and its possible relationship to cardiomyopathy*

The *in vitro* experiments have suggested that CD36 plays a role in taking up LCFA [14]. With the use of a radioactive analogue for LCFA, [ $^{123}$ I]-BMIPP: iodine-123 15-(p-iodophenyl)-(R, S), methylpentadecanoic acid], the heart of CD36-deficient patients was found to be defective in taking up BMIPP [15–17]. Cardiac muscle utilizes LCFA as a major energy source for maximum contractility, therefore CD36 deficiency may be related to the pathogenesis of cardiomyopathy [16].

#### *Phenotypic expression of the metabolic syndrome and insulin resistance in CD36-deficient patients*

We next investigated the phenotypic expression of 30 patients with type I CD36 deficiency (mean age: 62 years old). They had significantly higher serum triglycerides (TG) and lower HDL-cholesterol levels at fasting. Furthermore, oral fat loading test indicated CD36-deficient patients had a higher and delayed response of serum TG and apolipoprotein B48, a marker for intestine-derived lipids. They had a higher plasma glucose levels and blood pressure. The number of coronary risk factors in CD36 deficiency tended to be more than two. Thus, patients with CD36 deficiency showed some features of the metabolic syndrome. We tested whether these patients had insulin resistance. Although fasting plasma levels of glucose and insulin are used as parameters for insulin resistance in daily clinical settings, we used hyperinsulinemic euglycemic clamp, which is thought to be a more accurate way of evaluating insulin resistance. In all patients tested, whole body glucose uptake was reduced, indicating the presence of insulin resistance [18]. Furthermore, whole body glucose uptake was also reduced in younger subjects. Younger subjects with CD36 deficiency have been found to have a defective response of free fatty acids after glucose loading tests and some abnormalities in plasma lipoprotein levels [19, 20]. CD36-deficient patients showed postprandial hyperlipidemia with an increase in small intestine-derived lipids [21].

#### *Relationship of CD36 deficiency to coronary heart disease (CHD)*

A substantial number of CD36-deficient patients suffered from apparent CHD and cardiomyopathy. The frequency of CD36 deficiency was approximately 3-fold higher in patients with CHD than that in the control population (unpublished observation).

## Discussion

In the current study, we have characterized the phenotypic expression of CD36-deficient patients. We found that CD36 deficiency was accompanied by (1) hyperlipidemia and increased remnant lipoproteins, (2) impaired glucose metabolism based upon insulin resistance, and (3) mild hypertension. CD36 deficiency thus comprises one of the genetic backgrounds of the metabolic syndrome, leading to the development of CHD. What is the mechanism for these phenotypic expressions of the metabolic syndrome in CD36 deficiency? There are a couple of data that may possibly explain the mechanism. One is the altered dynamics of LCFA *in vivo*, which was demonstrated by the cardiac scintigram using an analogue of LCFA,  $^{123}\text{I}$ -BMIPP. We and others have reported that the uptake of BMIPP in the heart was totally absent in the CD36-deficient patients, indicating that CD36 may be a major receptor for LCFA in the human heart [15–17]. On the other hand, the uptake of LCFA was paradoxically increased in the patients' liver [22], where fatty acid transporters other than CD36 may be dominant. The increased flux of LCFA into the liver may lead to the enhanced production and secretion of very low density lipoproteins (VLDL) and hyperlipidemia as well as insulin resistance. The other is a possible impairment of the peroxisome proliferator activated receptor- $\gamma$  (PPAR- $\gamma$ ) pathway. As mentioned earlier, we and others have reported that CD36 expression was up-regulated by its ligand, Ox-LDL, as well as a synthetic ligand for PPAR- $\gamma$  [23]. In studies with human macrophages, CD36 appears to mediate intracellular signaling through PPAR- $\gamma$ . The synthetic ligands for PPAR- $\gamma$  such as thiazolidinediones are known to increase insulin sensitivity. CD36 deficiency could interfere with this pathway, causing the insulin resistance *in vivo*.

In many cases with multiple risk factors, the combination of genetic and acquired factors as well as the impact of each is important. In CD36 deficiency, the phenotype with the metabolic syndrome does not always appear to be manifest, but they already had subclinical abnormalities at their younger age [20]. In rodent models for CD36 deficiency, diets affected the phenotypic expression [24, 25]. CD36 deficiency has been found in some spontaneous hypertensive (SHR) rats expressing insulin resistance [24, 26]. Pravenec *et al.* [27] showed that glucose intolerance was observed under a high fructose diet in SHR rats and the transgene of wild-type CD36 corrected this phenotype. The SHR rats with CD36 mutation appeared to have heavier hearts than did controls, suggesting that abnormalities in CD36 are related to myocardial hypertrophy [28]. In CD36 null mice, hyperlipidemia [29] and insulin resistance [25] have been reported, which is similar to the above data from SHR rats with CD36 mutation. On the other hand, the original




Fig. 1. Pathophysiology of human CD36 deficiency. Macrophages from patients with CD36 deficiency are resistant to Ox-LDL-induced foam cell formation at least *in vitro*, which might be antiatherogenic. However, CD36 deficiency may be related to insulin resistance, the metabolic syndrome, atherosclerosis and cardiomyopathy. Altered dynamics of LCFA may be involved in the phenotypic expression of these disorders. Some acquired factors, including lifestyle, may modify the phenotypic expression. FFA: free fatty acids.

SHR rats did not have mutations in the CD36 gene [30]. Thus, CD36 deficiency may not be the only cause of insulin resistance in all strains of SHR. CD36 null mice were resistant to atherosclerosis in the apolipoprotein E-negative background [31]. Further investigation of the pathophysiological aspects of CD36 deficiency would provide important insights into the molecular mechanisms for the development of the metabolic syndrome and atherosclerotic cardiovascular diseases.

Regarding the atherogenicity, it appears that CD36 deficiency has both atherogenic and antiatherogenic aspects (Fig. 1): the former is the expression of the metabolic syndrome, which is most commonly found in patients with CHD; and the latter is the fact that in *in vitro* experiments, macrophages obtained from CD36-deficient patients were resistant to Ox-LDL-induced foam cell formation. In general, CD36 deficiency appears to be associated with atherogenic aspects. However, further clarification is needed with regard to how these contrasting aspects affect the atherogenicity and the phenotypes of CD36 deficiency.

## Conclusion

Human CD36 deficiency is accompanied by multiple risk factors such as hyperlipidemia, impaired glucose metabolism based upon insulin resistance, and a mild hypertension. Thus, it comprises one of the genetic backgrounds of the metabolic syndrome, leading to the development of CHD.

## Acknowledgments

The authors thank Drs. Shuichi Nozaki, Hirokazu Kashiwagi, and Yoshiaki Tomiyama for their mutational analyses of CD36-deficient patients and for helpful comments and discussions. This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology (No.08671157, 10671070, 11557055, 12835005, 13557093), Uehara Memorial Foundation and Yamanouchi Foundation for Research on Metabolic Disorders to S. Yamashita.

## References

1. Tandon NN, Lipsky RH, Burgess WH, *et al*: Protein isolation and characterization of platelet glycoprotein IV (CD36). *J Biol Chem* 264: 7570–7575, 1989.
2. Endemann G, Stanton IW, Madden KS, *et al*: CD36 is a receptor for oxidized low density lipoprotein. *J Biol Chem* 268: 11811–11816, 1993.
3. Nozaki S, Kashiwagi H, Yamashita S, *et al*: Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. *J Clin Invest* 96: 1859–1865, 1995.
4. Nagy L, Tontonoz P, Alvarez JG, *et al*: Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR $\gamma$ . *Cell* 93: 229–240, 1998.
5. Nakagawa T, Nozaki S, Nishida M, *et al*: Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. *Arterioscler Thromb Vasc Biol* 18: 1350–1357, 1998.
6. Nakata A, Nakagawa Y, Nishida M, *et al*: CD36, a novel receptor for oxidized low-density lipoproteins is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. *Arterioscler Thromb Vasc Biol* 19: 1333–1339, 1999.
7. Nakagawa Y, Yamashita S, Nozaki S, *et al*: Differential expression of CD36 and scavenger receptor class A type I and type II in human coronary arteries. *Atherosclerosis* 156: 297–305, 2001.
8. Febbraio M, Hajjar DP, Silverstein RI: CD36, a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation and lipid metabolism. *J Clin Invest* 108: 785–791, 2001.
9. Yamamoto N, Ikeda H, Tandon NN, *et al*: A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Nak<sup>a</sup> platelet lack detectable GPIV(CD36). *Blood* 76: 1698–1703, 1990.
10. Kashiwagi H, Honda S, Tomiyama Y, *et al*: A novel polymorphism in glycoprotein IV (replacement of proline-90 by serine) predominates in subjects with platelet GPIV deficiency. *Thromb Haemost* 69: 481–484, 1993.
11. Kashiwagi H, Tomiyama Y, Nozaki S, *et al*: Analyses of genetic abnormalities in type I CD36 deficiency in Japan: identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man. *Hum Genet* 108: 459–466, 2001.
12. Janabi MY, Yamashita S, Hirano K, *et al*: Reduced adhesion of monocyte-derived macrophages from CD36-deficient patients to type I collagen. *Biochem Biophys Res Commun* 283: 26–30, 2001.
13. Janabi M, Yamashita S, Hirano K, *et al*: Oxidized low density lipoprotein-induced activation of NF- $\kappa$ B and subsequent expression of a variety of proinflammatory and proatherogenic genes are defective in monocyte-derived macrophages from CD36-deficient patients. *Arterioscler Thromb Vasc Biol* 20: 1953–1960, 2000.
14. Abumrad NA, el-Maghrabi MR, Amri EZ, *et al*: Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. *J Biol Chem* 268: 17665–17668, 1993.
15. Nozaki S, Tanaka T, Yamashita S, *et al*: CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency. *Mol Cell Biochem* 192: 129–135, 1999.
16. Tanaka T, Sohmiya K, Kawamura K: Is CD36 deficiency an etiology of hereditary hypertrophic cardiomyopathy? *J Mol Cell Cardiol* 29: 121–127, 1997.
17. Tanaka T, Nakata T, Oka T, *et al*: Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutation. *J Lipid Res* 42: 751–759, 2001.
18. Miyaoka K, Kuwasako T, Hirano K, *et al*: CD36 deficiency is associated with insulin resistance. *Lancet* 357: 686–687, 2001.
19. Yanai H, Chiba H, Morimoto M, *et al*: Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. *Am J Med Genet* 93: 299–304, 2000.
20. Yanai H, Chiba H, Fujiwara H, *et al*: Metabolic changes in human CD36 deficiency displayed by glucose loading. *Thromb Haemost* 86: 995–999, 2001.
21. Kuwasako T, Hirano K, Sakai N, Ishigami M, Hiraoka H, Yakub MJ, Yamauchi-Takahara K, Yamashita S, Matsuzawa Y: Lipoprotein abnormalities in human genetic CD36 deficiency associated with insulin resistance and abnormal fatty acid metabolism. *Diabetes Care* 26: 1647–1648, 2003.
22. Yoshizumi T, Nozaki S, Fukuchi K, *et al*: Pharmacokinetics and metabolism of <sup>123</sup>I-BMIPP fatty acid analog in healthy and CD36-deficient subjects. *J Nucl Med* 41: 1134–1138, 2000.
23. Matsumoto K, Hirano K, Nozaki S, *et al*: Expression of macrophage scavenger receptor, CD36 in cultured human aortic smooth muscle cells, in association with the expression of peroxisome proliferators activated receptor- $\gamma$ . *Arterioscler Thromb Vasc Biol* 20: 1027–1032, 2000.
24. Aitman TJ, Glazier AM, Wallace CA, *et al*: Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. *Nat Genet* 21: 76–83, 1999.
25. Hajri T, Han XX, Bonen A, *et al*: Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. *J Clin Invest* 109: 1381–1389, 2002.
26. Glazier AM, Scott J, Aitman TJ: Molecular basis of the CD36 chromosomal deletion underlying SHR defects in insulin action and fatty acid metabolism. *Mamm Genome* 13: 108–113, 2002.
27. Pravenec M, Landa V, Zidek V, *et al*: Transgenic rescue of defective CD36 ameliorates insulin resistance in spontaneously hypertensive rats. *Nat Genet* 27: 156–158, 2001.
28. Hajri T, Ibrahimi A, Coburn CT, *et al*: Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. *J Biol Chem* 276: 23661–23666, 2001.
29. Febbraio M, Abumrad NA, Hajjar DP, *et al*: A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. *J Biol Chem* 274: 19055–19062, 1999.
30. Gotoda T, Iizuka Y, Kato N, *et al*: Absence of CD36 mutation in the original spontaneously hypertensive rats with insulin resistance. *Nat Genet* 22: 226–228, 1999.
31. Febbraio M, Podrez EA, Smith JD, *et al*: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. *J Clin Invest* 105: 1049–1056, 2000.

## SHORT REPORT

Osamu Sakamoto · Daiki Abukawa  
Junji Takeyama · Nobuhiro Arai · Makoto Nagano  
Hiroaki Hattori · Tohru Egashira · Naohiko Sakai  
Shizuya Yamashita · Kazuie Iinuma · Toshihiro Ohura

# An atypical case of abetalipoproteinaemia with severe fatty liver in the absence of steatorrhoea or acanthocytosis

Received: 2 February 2005 / Accepted: 29 June 2005 / Published online: 6 September 2005  
© Springer-Verlag 2005

Abetalipoproteinaemia (ABL; Bassen-Kornzweig syndrome; MIM 200100) is an autosomal recessive disease caused by a defective microsomal triglyceride-transfer protein (MTP) [5,6]. MTP is expressed in hepatocytes and intestinal enterocytes and may play a role in lipoprotein assembly via various functions such as lipid transfer, apolipoproteinB (apoB) binding, and membrane association [3]. Clinical manifestations of ABL include fat malabsorption, neuropathy, retinopathy, and acanthocytosis [2]. We describe here a hypolipidaemic infant with a fatty liver in the absence of steatorrhoea or acanthocytosis. Mutation analysis of the *MTP* gene to confirm the diagnosis revealed two novel mutations (IVS1 + 1G > C and I564T).

A male infant was first referred to Tohoku University Hospital at 15 months of age because of

hepatomegaly and liver dysfunction (aspartate aminotransferase 77 IU/l and alanine aminotransferase 151 IU/l). On admission, the infant had a body height and weight of 74.5 cm (-1.3 SD) and 9.9 kg (-1.5 SD), respectively. The liver margin was felt 3 cm below the right costal margin. An abdominal CT scan showed changes associated with a fatty liver (Fig. 1a). Blood lactate, pyruvate, amino acids, galactose, caeruloplasmin, and copper were all within the normal ranges. Urinary organic acid analysis by gas chromatography/mass spectrometry showed no specific findings. Glycogen storage diseases Ia, III, VI, and VIII were excluded by mutation analysis or enzyme assay. Mutation screening for the gene responsible for citrin deficiency (*SLC25A13*) failed to identify any of the 14 mutations previously reported. We found persistent decreases in serum cholesterol levels (46–92 mg/dl) and moderate decreases in triglycerides (10–100 mg/dl). Serum apoB was remarkably decreased (<7.0 mg/dl; reference range 73–109 mg/dl) and vitamin E was 0.43 mg/dl (reference range 0.75–1.41 mg/dl).

Microscopic examination of a liver biopsy performed at 4 years of age revealed a massive macrovesicular fatty abnormality of the hepatic parenchyma with fibrosis and infiltration of inflammatory cells in the portal area (Fig. 1b). Electron microscopy of the hepatocytes revealed huge fat droplets which were both cytosolic and non-membrane bound. The Golgi apparatus and endoplasmic reticulum were free of lipid-staining particles. All of these findings were compatible with ABL.

At the last examination at the age of 5 years, his body height and weight were 106.9 cm (-0.3 SD) and 16.9 kg (-0.5 SD), respectively. Retinol (1000 IU) and tocopherol (0.4 mg) were administered. No neurological or ophthalmological symptoms were found.

Mutation analysis of the *MTP* gene revealed a G-to-C substitution at the splicing donor site of intron 1 (IVS1 + 1G > C) and a T-to-C substitution (I564T) in exon 12 (Fig. 2a, b). The IVS1 + 1G > C and I564T mutations were transmitted from the patient's mother

---

O. Sakamoto · K. Iinuma · T. Ohura (✉)  
Department of Paediatrics, Tohoku University  
School of Medicine, 1-1 Seiryomachi, Aoba-ku,  
980-8574 Sendai, Japan  
E-mail: tohura@ped.med.tohoku.ac.jp  
Tel.: +81-22-7177287  
Fax: +81-22-7177290

D. Abukawa  
Department of General Paediatrics,  
Miyagi Children's Hospital, Sendai, Japan

J. Takeyama  
Department of Pathology, Miyagi Children's Hospital,  
Sendai, Japan


N. Arai  
Shiogama City Hospital,  
Shiogama, Japan

M. Nagano · H. Hattori · T. Egashira  
Department of Advanced Technologies and Development,  
BML Inc., Saitama, Japan

N. Sakai · S. Yamashita  
Department of Internal Medicine and Molecular Science,  
Osaka University Graduate School of Medicine, Osaka, Japan



**Fig. 1** **a** Abdominal CT scan showing remarkable fatty liver abnormalities. **b** Liver biopsy revealing a massive macrovesicular fatty alteration of the hepatic parenchyma and fibrosis in the portal area




and father, respectively (data not shown). Neither of the mutations was found in 50 healthy volunteers (data not shown). We speculate two possible explanations for the unusually mild phenotype of the present case. One explanation is that the functional defect of I564T may be milder than that of premature-termination mutations. Other patients with missense mutations also showed a mild phenotype [1,4]. An alternative and nonexclusive explanation would be that a splice-site mutation occasionally creates not only a splice-error transcript, but also normal

transcript at low levels. Expression and functional studies will need to be conducted to confirm these possibilities.

**Acknowledgements** We thank Drs. Yoichi Matsubara and Shigeo Kure (Tohoku University) for the glucose-6-phosphatase gene mutation screening; Dr. Hideo Sugie (Hamamatsu City Medical Centre for Developmental Medicine) for the enzyme assays of phosphorylase, phosphorylase b kinase, and debranching enzyme and Dr. Keiko Kobayashi (Kagoshima University Graduate School of Medical and Dental Sciences) for the *SLC25A13* mutation screening.



**Fig. 2** a Direct sequencing showing a G-to-C substitution at the splicing donor site of intron 1. b A T-to-C substitution was found in exon 12 (I564T)



## References

1. Al-Shali K, Wang J, Rosen F, Hegele RA (2003) Ileal adenocarcinoma in a mild phenotype of abetalipoproteinemia. *Clin Genet* 63: 135–138
2. Bassen FA, Kornzweig AL (1950) Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. *Blood* 5: 381–387
3. Hussain MM, Iqbal J, Anwar K, Rava P, Dai K (2003) Microsomal triglyceride transfer protein: a multifunctional protein. *Front Biosci* 8: 500–506
4. Ohashi K, Ishibashi S, Osuga J, Tozawa R, Harada K, Yahagi N, Shionoiri F, Iizuka Y, Tamura Y, Nagai R, Illingworth DR, Gotoda T, Yamada N (2000) Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. *J Lipid Res* 41: 1199–1204
5. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ, Aggerbeck LP, Gregg RE, Gordon DA, Wetterau JR (1993) Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinemia. *Nature* 365: 65–69
6. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, Schmitz J, Gay G, Rader DJ, Gregg RE (1992) Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. *Science* 258: 999–1001

## The Lipoprotein Fraction between VLDL and LDL Detected by Biphasic Agarose Gel Electrophoresis Reflects Serum Remnant Lipoprotein and Lp(a) Concentrations

Itsuko Sato<sup>1</sup>, Takahiro Taniguchi<sup>2</sup>, Yuichi Ishikawa<sup>3</sup>, Mari Kusuki<sup>1</sup>, Fujio Hayashi<sup>1</sup>, Masahiko Mukai<sup>1</sup>, Seiji Kawano<sup>1,6</sup>, Shinichi Kondo<sup>4</sup>, Shizuya Yamashita<sup>5</sup>, and Shunichi Kumagai<sup>1,6</sup>

<sup>1</sup> Clinical Laboratory, Kobe University Hospital, Kobe, Japan.

<sup>2</sup> Division of Cardiovascular and Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

<sup>3</sup> Faculty of Health Sciences, Kobe University School of Medicine, Kobe, Japan.

<sup>4</sup> Department of Internal Medicine, Kakogawa Municipal Hospital, Hyogo, Japan.

<sup>5</sup> Department of Internal Medicine and Molecular Science, Osaka University Graduate School of Medicine, Osaka, Japan.

<sup>6</sup> Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.

We analyzed lipoprotein profiles in 616 Japanese by biphasic agarose gel electrophoresis using Chol/Trig Combo™ to yield HDL, VLDL, LDL and CM fractions which were stained with cholesterol and triglyceride reagents, respectively. To further evaluate the pattern of electrophoresis, we analyzed the fraction between VLDL and LDL to confirm the possibility of a MidBand by using an automatic-five-fraction function. The cholesterol concentrations in MidBand (MidBand-C) showed a good correlation to remnant-like particle-cholesterol (RLP-C) ( $r = 0.95$ ) in 23 consecutive samples (TC < 220 mg/dl, Lp(a) < 30 mg/dl). However, MidBand-C concentrations of subjects with high Lp(a) levels (Lp(a) > 30 mg/dl) were also high compared to RLP-C concentrations. The average MidBand-C levels in elderly normolipidemic control subjects (TC < 220, TG < 150) were  $5.2 \pm 2.4$  mg/dl in 30 males (mean age,  $70 \pm 10$  years) and  $5.4 \pm 2.0$  mg/dl in 40 females ( $64 \pm 11$  years). The average MidBand-C levels of normolipidemic patients with coronary artery diseases (CAD; TC < 220, TG < 150) were  $9.4 \pm 4.1$  mg/dl in 126 males (mean age,  $66 \pm 10$  years) and  $9.1 \pm 4.0$  mg/dl in 44 females ( $67 \pm 10$  years). These levels were significantly higher than control values ( $p < 0.0001$ ). Areas under ROC curves were greater for MidBand-C than for TC, LDL-C and TG when used to discriminate between the patients with CAD and normolipidemic control subjects for each sex. These results suggest that the MidBand-C level may be useful as an indicator of risk for CAD. *J Atheroscler Thromb*, 2006; 13: 55–61.

**Key words:** Agarose gel electrophoresis, Automatic five-fraction, Remnant like particles-cholesterol, Coronary artery disease.

### Introduction

The major remnant lipoproteins are a mixture of the exogenous chylomicron remnant derived from the intestine and the endogenous very low density lipoprotein (VLDL) remnant (IDL) derived from the liver. Methods have been developed to measure remnant lipoproteins. Remnant lipoproteins have been identified as atherogenic (1).

Address for correspondence: Itsuko Sato, Clinical Laboratory, Kobe University Hospital, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

E-mail: itsuko@med.kobe-u.ac.jp

Received January 28, 2004

Accepted for publication November 7, 2005

We reported that serum levels of remnant-like particle cholesterol (RLP-C) were increased in patients with diabetes and impaired glucose tolerance (2). We also reported that remnant lipoproteins had unique biological effects such as the induction of apoptosis of cultured endothelial cells (3). VLDL remnants can be separated by the ultracentrifugal method at a density of 1.006–1.019 g/ml (4). However, this method is not suitable for routine analysis, because it takes hours, and the processing of multiple specimens is difficult (5).

Agarose gel electrophoresis is an authentic method of detecting remnant lipoprotein which appears as a broad band. The mid-band in polyacrylamide gel electrophoresis is also well known as the band of remnant lipoprotein (4). However, these methods are qualitative not quantitative. Recently a quantitative assay for RLP-C has been developed (6), and an elevation of plasma RLP-C levels was reported in patients with coronary artery diseases (CAD) (7). But there are considerable numbers of patients with type I and V hyperlipidemia whose levels of RLP-C appear abnormal in immunoadsorption assays with antibody. Therefore, it is important to develop simple and comprehensive methods to measure remnant lipoprotein levels.

We analyzed the lipoprotein fractions by using the agarose gel electrophoresis with Chol/Trig Combo™, which can quantify each lipoprotein fraction on the basis of the separate staining of cholesterol and TG and by automatic analysis. Based on this method, it is possible not only to measure the levels of HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) quantitatively, but also to recognize the entire pattern of lipoprotein fractions (8–11). We identified the fraction between the VLDL and LDL fractions using the Automatic five-fraction function of Chol/Trig Combo™ and elucidated that this fraction was closely related to the levels of RLP-C and increased in CAD patients compared with normolipidemic subjects. We named this fraction MidBand and clarified its clinical significance.

## Methods

### Study subjects

We measured RLP-C and Lp(a) concentrations in 64 patients [31 males (mean age  $60 \pm 11$  years, age range 31–81 years) and 33 females ( $63 \pm 16$ , 26–80 years)], who requested a RLP-C test between 2000.03 and 2003.03.

The elderly control subjects were the 80 normolipidemic (TC 114–219 mg/dl, TG < 150 mg/dl) staff members of the Kobe University hospital enrolled in an annual medical checkup and patients 60 years or older who were free from CAD, liver disease, kidney disease and diabetes mellitus who were selected from among patients at Kobe University Hospital. These were 35 males (mean age  $66 \pm 13$  years, age range 41–90 years) and 45 fe-

males ( $64 \pm 12$ , 50–88 years)

To evaluate the clinical usefulness of MidBand-C in CAD, 168 patients with CAD (TC 80–219 mg/dl, TG < 150 mg/dl) were admitted to Kobe University hospital and their diagnosis was confirmed by coronary angiography. This group consisted of 125 males (mean age  $67 \pm 10$  years, age range 35–88 years) and 43 females ( $68 \pm 9$ , 47–83 years).

Hospital staff were ordered with informed consent to come to blood sampling in the fasting state. Sera from the patients with CAD were drawn in a 12-hour fasted state with venopuncture. These samples were made anonymous without linking.

### Biochemical analysis

Serum total cholesterol (TC) and TG concentrations were measured using an auto analyzer TBA-80M (TOSHIBA, Tokyo, Japan) by the enzymatic method. The RLP-C concentration was measured by the immune adsorption method (JIMROII, Japan). The serum Lp(a) concentration was measured using an auto analyzer TBA-80FR (TOSHIBA) by the latex agglutination immunoassay.


### Agarose gel electrophoresis analysis

The serum samples were subjected to the lipoprotein analysis using agarose gel electrophoresis (Rapid Electrophoresis, Helena Laboratories, Beaumont, Texas) and the gels were stained with cholesterol and TG reagent. The conditions for electrophoresis were as follows; serum application volume was  $1\mu$ , and electrophoresis time was 18 min at 400 volts, and 20°C. Elution profiles were analyzed by an automatic densitometer, Chol/Trig Combo™ (Helena Kennkyusyo, Saitama, Japan).


Apolipoprotein B48 (apoB48) and Apolipoprotein B100 (B100) were identified with immunoblotting on the nitrocellulose film where the agarose gels were transferred. For detecting apo B48 and apo B100, we used anti-apoB48-151 monoclonal antibody (Fujirebio Co, Tokyo, Japan) and anti-apo B100 monoclonal antibody (Biochemical Division, Ohio), respectively. Ofuto® cream (Milk fat 35%, 547 kcal. Jyoumou Shokuhin company, Gunma, Japan) was used in the fat load. The samples which could not be measured on the day were stored at  $-40^\circ\text{C}$  with the addition 1/20 (vol/vol) of dimethyl sulfoxide (8). This preservation method was effective up to four weeks (data not shown).

### Statistical analysis

Data are expressed as the mean  $\pm$  SD. Pearson's Correlation coefficient was used for the relationship between MidBand-C and RLP-C. Differences were examined with Student's *t* test. The computer analysis was done using Stat View Ver. 5.0. A *p*-value less than 0.01 was considered statistically significant. Receiver-operative charac-



**Fig. 1.** Electrophoregram of cholesterol fractions, triglyceride fractions, apo B48 or apo B100. Apo B48 and apo B100 were detected by immunoblotting with anti -apo B48 or anti-apo B100 antibody. Sera were electrophoresed 4 hours after fat load (Ofuto™)



**Fig. 2.** The representative densitometric scanning patterns for Chol/Trig Combo™. (A): cholesterol stain (B): triglyceride stain (C): layer in A and B (D): an example of a normolipidemic control subject, TC 202, TG 86, HDL-C 65, Mid Band-C 2.0, RLP-C < 2.5 (mg/dl)

teristics curve analysis was used to show performance figures. For the computation and analysis of ROC curves, we used the software program Med Calc, Ver. 6.01 (Med Calc Software).


## Results

### Determination of MidBand

We established automatic-five-fraction on the strength of the electric charge with apolipoprotein. The fraction eluted between the VLDL and LDL fractions in agarose gel electrophoresis of Chol/Trig Combo™ was defined as MidBand.

To confirm whether MidBand was rich in apoB48, serum was selected 4 hours after the loading of fat (Ofuto™) and electrophoresed and transferred to a nitrocellulose membrane. Nitrocellulose membrane was immunoblotted with anti-human apoB48 antibody and compared with the electrophoregram of cholesterol fractions, TG fractions and fractions immunoblotted with anti apoB100 antibody. MidBand was rich in apoB48, and the LDL fraction was rich in apoB100 (Fig. 1).

For example, agarose gels were stained for cholesterol (Fig. 2A) or TG (Fig. 2B) after electrophoresis and analyzed by the automatic densitometer Chol/Trig Combo™. After both patterns were imposed as shown in Fig. 2C,



**Fig. 3.** Yellow dots: A significant positive correlation between MidBand-C levels and RLP-C levels when TC < 220 mg/dl and Lp(a) < 30 mg/dl.

Red dots: Lp > 30 mg/dl

Blue dots: TC > 220 mg/dl and Lp(a) < 30 mg/dl

RLP-C: Remnant-like particle cholesterol

MidBand was determined as the fraction between LDL and VLDL fractions. A representative profile of a normolipidemic subject is shown in Fig. 2D. The MidBand-cholesterol (MidBand-C) concentration was calculated from the serum cholesterol level and percentage of MidBand in the cholesterol fraction of the agarose gel electrophoretogram.

#### Relationship among MidBand-C, RLP-C and Lp(a)

To evaluate the relationship between MidBand-C and RLP-C, we measured RLP-C concentrations of 64 subjects and compared them to MidBand-C concentrations. We selected 23 subjects with both a TC of less than 220 mg/dl and Lp(a) concentration of less than 30 mg/dl out of the 64 subjects. As shown in Fig. 3 (yellow dot), there was a significant positive correlation between concentrations of MidBand-C and RLP-C in subjects with a correlation coefficient ( $r$ ) of 0.95 ( $p < 0.001$ ). However, MidBand-C concentrations of hyperlipidemic patients deviated from the standard line (Fig. 3, red dot and blue dot). MidBand-C concentrations of subjects with high Lp(a) levels were also high compared with RLP-C concentrations. As we have already reported, Lp(a) at levels of more than 30 mg/dl migrates as a peak of cholesterol between VLDL and LDL using this method (13). This position is the same as that of MidBand. Representative elution profiles are shown in Fig. 4. In sample A, the Lp(a) concentration was 142 mg/dl showing a sharp MidBand-C peak. Sample B was from a type IIb hyperlipidemic patient and MidBand-C is the mid-band. Sample C was obtained from a type III hyperlipidemic patient and had

a broad beta-band in the lipoprotein fraction. Sample D showed the presence of chylomicron and a high concentration of VLDL-TG, indicating type V hyperlipidemia.

#### Comparison of MidBand-C levels of normolipidemic subjects with patients with CAD


Table 1 shows a summary of the clinical characteristics of the elderly control subjects and the patients with CAD. Significant differences in HDL-C and MidBand-C concentrations were observed between the two groups in each sex.

To elucidate the clinical significance of MidBand-C in CAD, we measured the MidBand-C concentrations of the patients with CAD. Mean MidBand-C concentrations were  $9.4 \pm 4.1$  and  $9.2 \pm 4.0$  mg/dl in the male and female patients, and significantly higher than in control subjects ( $p > 0.0001$ ) (Fig. 5).

A ROC analysis was performed for MidBand-C, HDL-C, LDL-C, TC and TG in the CAD patients and control subjects in males (Fig. 6) and females (Fig. 7). The area under the ROC curve (AUC) for MidBand-C in males and females was 0.80 and 0.79, respectively, showing a significant difference from that for LDL-C, TC and TG. ROC curves of HDL-C and MidBand-C almost overlapped and there was no significant difference.

#### Discussion

In the present study, we demonstrated that MidBand-C concentrations analyzed by agarose gel electrophoresis and automatic densitometer showed a significant correlation with RLP-C concentrations. MidBand is consid-



**Fig. 4.** Densitometric scanning patterns of hyperlipidemia.

Patient A had type IIa hyperlipidemia, and the mid-band; TC 311, TG 41, RLP-C 2.9, MidBand-C 39.5, Lp(a) 142 mg/dl. Patient B had type IIb hyperlipidemia, and the mid-band; TC 252, TG 264, RLP-C 9.0, MidBand-C 46.4 mg/dl. Patient C had type III hyperlipidemia, and a broad beta-band in the lipoprotein fraction; TC 232, TG 342, RLP-C 12.0, MidBand-C 58.0 mg/dl. Patients D had the type V hyperlipidemia, and an increase of chomicron; TC 167, TG 967, RLP-C 71.0, MidBand-C 14.0 mg/dl.

**Table 1.** Clinical characteristics of CAD patients and elderly control subjects

	Men		Female	
	control (n = 35)	CAD (n = 125)	control (n = 45)	CAD (n = 43)
Age (year)	66.1 ± 12.6	66.7 ± 9.6	63.7 ± 11.5	68.1 ± 9.3
TC (mg/dl)	164.7 ± 30.7	169.3 ± 29.7	178.7 ± 22.3	173.3 ± 24.5
TG (mg/dl)	86.0 ± 28.8	92.2 ± 30.7	92.0 ± 23.4	98.5 ± 28.3
LDL-C (mg/dl)	104.7 ± 24.2	103.9 ± 26.4	92.1 ± 20.8	104.5 ± 22.5
HDL-C (mg/dl)	61.3 ± 14.4	42.4 ± 13.3*	69.4 ± 17.5	47.4 ± 13.9**
MidBand-C (mg/dl)	5.2 ± 2.3	9.4 ± 4.1*	5.5 ± 2.0	9.2 ± 3.9**

\* Significantly different from the value of control men,  $p < 0.0001$


\*\* Significantly different from the value of control female,  $p < 0.0001$

ered similar to the mid-band observed in polyacrylamide gel electrophoresis (PAGE). However, it is not possible to conduct a quantitative analysis of remnant lipoproteins by PAGE. Additionally, preparative and analytical ultracentrifugation methods have been used to separate VLDL and IDL. However these methods are labor-intensive and complex. With our method using Chol/Trig Combo™, the operation is simple and semi-automated. Moreover, one is able not only to recognize the entire lipoprotein profile but also to quantitate the cholesterol and TG of MidBand that is equivalent to the IDL or remnant lipoprotein. We demonstrated that the MidBand



richly contained apo B48.

To investigate the relation between MidBand-C and RLP-C, we measured RLP-C concentrations of 23 subjects with both a TC concentration of less than 220 mg/dl and a Lp(a) concentration of less than 30 mg/dl. In these subjects, there was a significant correlation between RLP-C and MidBand-C. Moreover, Lp(a) at levels of more than 30 mg/dl migrates as the same peak as MidBand-C. These results suggested that MidBand-C reflected VLDL remnants and Lp(a). Both are known to be atherogenic.

We analyzed MidBand-C in 80 elderly control subjects. To investigate the significance of the MidBand-C con-



**Fig. 5.** Levels of MidBand-C in the elderly normolipidemic control subjects and the normolipidemic patients with CAD. There was a significant difference in MidBand-C levels between the control and CAD in each sex.



**Fig. 6. and Fig. 7.** Receiver operating characteristic curves of MidBand-C, HDL-C, LDL-C, TC and TG when used to discriminate between the patients with CAD and control subjects in males and females. AUC: Area under the curve.

centration in CAD, we measured levels in 168 patients with CAD. Mean MidBand-C levels of CAD patients ( $9.4 \pm 4.1$  mg/dl and  $9.2 \pm 3.9$  mg/dl in males and females, respectively) were significantly higher than those of elderly control subjects ( $5.2 \pm 2.3$  mg/dl and  $5.5 \pm 2.0$  mg/dl,  $p < 0.0001$ ). In the ROC analysis performed on CAD patients and control subjects, the AUC for MidBand-C was 0.80 for males and 0.79 for females. In addition, the AUC of MidBand-C was significantly higher than that for LDL-C, TC or TG, suggesting that the elevation in the concentration of MidBand-C could be a useful marker of the risk of developing CAD.

Considering these results, measurements of MidBand-C made using Chol/Trig Combo™ may be important to evaluate the risk of CAD.

### Conclusion

We defined MidBand as the fraction between LDL and the VLDL fractions in Chol/Trig Combo™. MidBand-C reflected the serum levels of RLP-C and Lp(a), and may be an important index with which to estimate the risk of CAD.



## References

- (1) Havel RJ: Postprandial hyperlipidemia and remnant lipoproteins. *Curr Opin Lipidol*, 5: 102–109, 1994
- (2) Watanabe N, Taniguchi T, Taketoh H, Kitagawa Y, Namura H, Yoneda N, Kurimoto Y, Yamada S, and Ishikawa Y: Elevated Remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. *Diabetes care*, 22: 152–156, 1999
- (3) Kawasaki S, Taniguchi T, Fujioka Y, Takahashi A, Takahashi T, Domoto K, Taguchi M, Ishikawa Y, and Yokoyama M: Chylomicron remnant induces apoptosis in vascular endothelial cells. *Ann NY Acad Sci*, 902: 336–341, 2000
- (4) Nozaki S, Yamashita S, and Matsuzawa Y: Accumulation of Remnant Lipoprotein- Evaluation and Its Mechanism. *Atherosclerosis*, 26: 279–282, 1999
- (5) Takeuchi N and Saheki Y: Evaluation and Problems of Ultracentrifugal Techniqal for Separation and Analysis of Serum Lipoprotein. Comparison with Other Analytical Methods. *Jpn J Pahol*, 41: 750–758, 1993
- (6) Akuzawa K, Nakano T, Sekiuchi I, Shimoyama M, Adachi M, Tange S, Tanaka A, Tada N, and Nakajima K: Remnant-like Particls-cholesterol (RLP-C) Assay and its Clinical Application to Lipid Tests in a Postprandial as well as Fasting State. *Jpn J Pathol*, 43: 1159–1167, 1995
- (7) Leary ET, Wang T, and Baker DJ: Evolution of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. *Clin Chem*, 448: 2490–2498, 1998
- (8) Kido T, Kurata H, Iwamoto T, Utsunomiya K, Matsumoto A, Tajima N, Itakura H, and Kondo K: Clinical application of apolipoprotein analysis by agarose gel electrophoresis. *The Lipid*, 9: 487–494, 1998
- (9) Tsukamoto H, Hukada H, Ootake T, Kikuchi H, and Watanabe K: Evaluation of New Computer System for Analysis of Serum Lipoprotein Electrophoresis; Comparison with Ultracentrifugal Analysis. *JJCLA*, 25: 723–729, 2000
- (10) Tanaka M, Inada Y, and Yoshino G: Detection of modified lipoproteins employing specific antibodies against apolipoproteins by Chol/Trig Combo™ and its clinical application. *Jpn J Med Pharm Sci*, 50: 551–556, 2003
- (11) Muraoka K, Kiyohara Y, Kikuchi M, Tagawa N, Maeda A, and Kobayashi Y: Pathological Analysis of Hyperlipidemia by a Newly Developed Agrose Electrophoreses. *Rinsho Kagaku*, 31: 266–274, 2002 (Japanese)
- (12) Nakazato I, Hisamura A, Morishima S, Furuta K, and Nishio H: On saving method of the serum sample for the lipid electrophoresis. *Sample kenkyukai*, 15: 35, 2001 (Japanese)
- (13) Hyakuta M, Sato I, Hayasi F, Mukai M, Kondo S, and Kumagai S: Reason of Lp(a) Not Appearing as a Mid-band with the Chol/Trig Combo. *JJCLA*, 28: 52–58, 2003 (Japanese)

# Arteriosclerosis, Thrombosis, and Vascular Biology

JOURNAL OF THE AMERICAN HEART ASSOCIATION



*Learn and Live* SM

## Angiotensin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

Mitsuru Shimamura, Morihiro Matsuda, Hiroaki Yasumo, Mitsuyo Okazaki, Kazunori Fujimoto, Keita Kono, Tetsuya Shimizugawa, Yosuke Ando, Ryuta Koishi, Takafumi Kohama, Naohiko Sakai, Kazuaki Kotani, Ryutaro Komuro, Tatsuo Ishida, Kenichi Hirata, Shizuya Yamashita, Hidehiko Furukawa and Iichiro Shimomura  
*Arterioscler. Thromb. Vasc. Biol.* 2007;27:366-372; originally published online Nov 16, 2006;

DOI: 10.1161/01.ATV.0000252827.51626.89

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association.  
7272 Greenville Avenue, Dallas, TX 75214

Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://atvb.ahajournals.org/cgi/content/full/27/2/366>

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at  
<http://atvb.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21202-2436. Phone 410-5280-4050. Fax: 410-528-8550. Email: [journalpermissions@lww.com](mailto:journalpermissions@lww.com)

Reprints: Information about reprints can be found online at  
<http://www.lww.com/static/html/reprints.html>

# Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

Mitsuru Shimamura, Morihiro Matsuda, Hiroaki Yasumo, Mitsuyo Okazaki, Kazunori Fujimoto, Keita Kono, Tetsuya Shimizugawa, Yosuke Ando, Ryuta Koishi, Takafumi Kohama, Naohiko Sakai, Kazuaki Kotani, Ryutaro Komuro, Tatsuo Ishida, Kenichi Hirata, Shizuya Yamashita, Hidehiko Furukawa, Ichiro Shimomura

**Objectives**—A low level of high-density lipoprotein (HDL) in plasma has been recognized as an aspect of metabolic syndrome and as a crucial risk factor of cardiovascular events. However, the physiological regulation of plasma HDL levels has not been completely defined. Current studies aim to reveal the contribution of angiopoietin-like protein3 (angptl3), previously known as a plasma suppressor of lipoprotein lipase, to HDL metabolism.

**Methods and Results**—Angptl3-deficient mice showed low plasma HDL cholesterol and HDL phospholipid (PL), and which were increased by ANGPTL3 supplementation via adenovirus. In vitro, ANGPTL3 inhibited the phospholipase activity of endothelial lipase (EL), which hydrolyzes HDL-PL and hence decreases plasma HDL levels, through a putative heparin-binding site in the N-terminal domain of ANGPTL3. Post-heparin plasma in Angptl3-knockout mice had higher phospholipase activity than did that in wild-type mice, suggesting that the activity of endogenous EL is elevated in Angptl3-deficient mice. Furthermore, we established an ELISA system for human ANGPTL3 and found that plasma ANGPTL3 levels significantly correlated with plasma HDL cholesterol and HDL-PL levels in human subjects.

**Conclusions**—Angptl3 acts as an inhibitor of EL and may be involved in the regulation of plasma HDL cholesterol and HDL-PL levels in humans and rodents. (*Arterioscler Thromb Vasc Biol.* 2007;27:366-372.)

**Key Words:** angptl3 ■ high density lipoprotein ■ endothelial lipase ■ phospholipase ■ triglyceride

Plasma concentrations of high-density lipoprotein (HDL) cholesterol are inversely correlated with the risk of atherosclerotic cardiovascular disease.<sup>1</sup> HDL cholesterol levels are low in patients with metabolic disorders, such as obesity, insulin resistance, and diabetes.<sup>2,3</sup> However, the genetic and metabolic factors that regulate HDL metabolism remain to be elucidated. Recently, endothelial lipase (EL) has been recognized as one factor that influences HDL metabolism. EL was originally discovered as a member of the family of triglyceride (TG)-lipases together with lipoprotein lipase (LPL) and hepatic lipase (HL). In contrast to LPL or HL, however, EL has relatively lower triglyceride lipase activity and substantially higher phospholipid lipase activity and can hydrolyze HDL phospholipids (PL).<sup>4</sup> Overexpression of EL in mice resulted in reduced plasma HDL levels and EL knockout mice showed significant increase in HDL levels,<sup>5-7</sup> indicating that EL regulates HDL metabolism.

In the colony of KK mice, characterized by obesity, diabetes mellitus, and hypertriglyceridemia, we recently iden-

tified a mutant subgroup of KK/Snk mice with low plasma TG levels despite maintaining the phenotype of obesity and diabetes. Genetic mapping and positional cloning identified the gene of angiopoietin-like protein 3 (Angptl3), which was mutated in the KK/Snk mice. The Angptl3 gene in KK/Snk mice contained a 4-bp nucleotide insertion in exon 6, which caused a premature stop codon attributable to a frameshift, leading to a lack of production of the protein.<sup>8</sup> Angptl3 mRNA is expressed exclusively in the livers of humans and mice. ANGPTL3 protein contains a signal sequence of 18 amino acids at the N terminus, followed by a coiled-coil domain and a fibrinogen-like domain at the C-terminal side.<sup>8,9</sup> Treatment with recombinant ANGPTL3 or adenovirus-mediated overproduction of ANGPTL3 significantly elevated plasma levels of TG, nonesterified fatty acids (NEFA), and total cholesterol in mice.<sup>8</sup> In subsequent studies, we revealed that ANGPTL3 increased very low density lipoprotein (VLDL)-TG levels by inhibiting LPL activity via the putative heparin-binding motif in the N-terminal re-

Original received January 29, 2006; final version accepted October 5, 2006.

From the Department of Medicine and Pathophysiology (M.S., M.M., I.S.), Graduate School of Frontier Bioscience; Department of Metabolic Medicine (M.M., N.S., R.Komuro, I.S.), Department of Cardiovascular Medicine (S.Y.), Graduate School of Medicine, Osaka University, Osaka, Japan; Biomedical Research Laboratories (M.S., H.Y., R.Koishi, T.K., H.F.), Pharmacology and Molecular Biology Research Laboratories (K.Kono, T.S., T.K.), Sankyo Co. Ltd., Tokyo, Japan; Medical Safety Research Laboratories (K.F., Y.A.), Sankyo Co. Ltd., Shizuoka, Japan; Laboratory of Chemistry (M.O.), College of Liberal Arts and Sciences, Tokyo Medical and Dental University, Chiba, Japan; Sekiyama Clinic, Osaka Health Club (K.Kotani), Osaka, Japan; Division of Cardiovascular and Respiratory Medicine (T.I., K.H.), Kobe University Graduate School of Medicine, Kobe, Japan. Current affiliation (N.S.), Itami City Hospital, Hyogo, Japan.

Correspondence to Morihiro Matsuda, MD, PhD, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan. E-mail mmatsuda@imed2.med.osaka-u.ac.jp  
© 2007 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol.* is available at <http://www.atvbaha.org>

DOI: 10.1161/01.ATV.0000252827.51626.89

gion.<sup>10,11</sup> In another study, we also found that ANGPTL3 was able to bind to adipocytes and increase the release of NEFA through activating lipolysis.<sup>12</sup> Thus, the molecular mechanisms of ANGPTL3-mediated increase in plasma TG and NEFA have been investigated. However, the effects of ANGPTL3 on plasma total cholesterol, especially on plasma HDL which is the major lipoprotein carrying cholesterol in mice, have not yet been investigated.

Moreover, the amino acid sequence of EL is 44% identical to that of LPL, and in particular, the clusters of positively charged residues involved in heparin binding are conserved between EL and LPL,<sup>13</sup> suggesting that ANGPTL3 might affect EL activity, because it inhibits LPL activity. In the current study, we investigated the potential involvement of ANGPTL3 in HDL metabolism and its effects on EL activity.

## Methods

### Animals

Studies were conducted in 15- to 19-week-old male wild-type KK and Angptl3-deficient KK/Snk mice. To obtain a congenic strain, KK/Snk mice were backcrossed to C57BL/6J mice for 10 generations, and designated as C57BL/6J Angptl3<sup>hypl</sup> mice.<sup>14</sup> Angptl3-knock out mice were made as described previously.<sup>15</sup> Experiments were conducted when the mice (males) were between 8 and 9 weeks of age. The mice were housed in a room under controlled temperature (23 ± 1°C) with free access to water and mouse chow (Oriental Yeast). Blood samples were taken from the inferior vena cava after anesthetization with pentobarbital (50 mg/kg, injected intraperitoneally). Plasma Angptl3 was measured using an Enzyme-linked immunosorbent assay (ELISA) for mouse protein as described previously.<sup>14,16</sup> Plasma HDL cholesterol, total cholesterol, and TG concentrations were measured using assay kits from Wako Pure Chemical Industries. Briefly, to determine HDL-cholesterol and HDL-PL, plasma samples were mixed with reagent to precipitate a non-HDL fraction including magnesium chloride and phosphotungstic acid.<sup>17</sup> The supernatant containing the HDL fraction was harvested and the cholesterol and PL contents were measured with the assay kits (Wako).

### Adenovirus Construction

Adenovirus expression vectors containing  $\beta$ -galactosidase (LacZ; designated Ad/lacZ) and human ANGPTL3 (designated Ad/ANGPTL3) cDNAs were constructed as described previously.<sup>8,10</sup> We injected 1 or 2 × 10<sup>9</sup> pfu of each recombinant adenovirus intravenously into C57BL/6J Angptl3<sup>hypl</sup> mice.<sup>14</sup>

### Lipoprotein Analysis

Plasma lipoproteins were analyzed by an upgraded high performance liquid chromatography (HPLC) analysis according to the procedure described by Usui et al<sup>18,19</sup> (Skylight Biotech Inc).

### Recombinant ANGPTL3 Protein

Human recombinant ANGPTL3 protein was prepared as described previously, and it was confirmed to inhibit LPL in vitro and to increase plasma TG concentrations in mice.<sup>8,10</sup> Recombinant proteins of truncated and/or mutated human ANGPTL3 were prepared as described previously.<sup>11</sup>

### Phospholipase Activity

To obtain EL protein, we constructed human EL cDNA adding an in-frame DNA sequence, as described previously.<sup>13</sup> Human expression constructs were transfected into HEK293 cells with Lipofectamine2000 (Life Technologies), and then a stable transfectant was obtained by G418 selection. The stable transfectant cells were

incubated with Opti-MEM I (Invitrogen). After 48 hours, the conditioned (heparin-washed) media were harvested as the enzyme solution, and phospholipase activities were measured with recombinant ANGPTL3 proteins as described in supplemental Methods (available online at <http://atvb.ahajournals.org>). For the quantification of phospholipase activity in mouse plasma, studies were conducted in 11- to 13-week-old male C57/BL6 and C57/BL6 Angptl3-knockout mice. Plasma was collected into tubes, using a heparin-coated glass capillary, before and 10 minutes after the heparin (20U/kg) injection into the jugular vein. 20  $\mu$ L of mouse plasma was used as an enzyme solution, and phospholipase activities were measured as described in supplemental Methods.

### ELISA for Plasma ANGPTL3 in Humans

Two ANGPTL3 mouse antibodies were produced using the recombinant human ANGPTL3 as the antigen, and were introduced in a double-antibody sandwich enzyme immunoassay system (ELISA) to detect human ANGPTL3.<sup>8,10,14,16</sup> 45B1 mouse monoclonal antibody was fixed on the 96-well plates. 16-fold diluted plasma samples were immobilized on the 96-well plates at 4°C for 16 hours. Then, we washed the plates with PBS containing 0.1% tween20 (PBST) and added horseradish peroxidase (HRP)-conjugated No.1 rabbit polyclonal antibody to these plates. After 1 hour incubation at 37°C, we washed the plates with PBST and added the detection reagent for HRP. Thirty minutes later, we stopped the reaction by the addition of an equal volume of 1N H<sub>2</sub>SO<sub>4</sub> and measured at 450 nm absorbance.

### Western Blotting

Western blotting of recombinant human ANGPTL3 protein was conducted as described previously.<sup>11</sup> The plasma protein bound to the ELISA plate fixed with 45B1 mouse monoclonal antibody was subjected to western blotting with HRP-conjugated No.1 rabbit polyclonal antibody.

### Human Studies

87 volunteers working at Sankyo Co. were enrolled in the study. All subjects gave informed consent. Several subjects with obesity, hypertriglyceridemia, hypertension, fatty liver, diabetes, kidney failure, low body weight, and detection of blood in the urea, were excluded from the correlation analyses. Subjects taking drugs for hyperlipidemia also were excluded. Plasma samples were collected under overnight fasting conditions. Total cholesterol and TG concentrations were measured using an automatic analyzer from Wako Pure Chemical Industries. HDL cholesterol and HDL-PL concentrations were measured as described above.


### Statistical Analysis and Ethical Considerations

The correlation coefficient (r) and probability (p) were calculated in human studies using Microsoft Excel 2003. All data were expressed as the means ± SEM or SD. Differences between the groups were examined for statistical significance using a Student *t* test. A probability value less than 0.05 denoted the presence of a statistically significant difference. All study protocols described in this report were approved by the Human and Animal Experimentations Ethics Review Committees of Sankyo.

## Results

### Low HDL lipids Were Observed in the Plasma of Angptl3-Deficient Mice

Figure 1A shows the plasma lipid concentrations in wild-type KK mice (n=5) and KK/Snk mice (n=5). Plasma Angptl3 was not detected in KK/Snk mice (29 ± 4.9 ng/mL versus not detected, *P* < 0.001, Figure 1A). The levels of plasma HDL cholesterol and HDL-PL were significantly lower in KK/Snk mice than in KK mice (41 ± 4.1 versus 79 ± 3.9 mg/dL, *P* < 0.001; 105 ± 13.7 versus 233 ± 13.3 mg/dL, *P* < 0.001,



**Figure 1.** HDL cholesterol, HDL-PL, and triglyceride concentrations in Angptl3-deficient mice. A, Plasma levels of Angptl3, HDL cholesterol (HDL chol), HDL-PL, and triglyceride were measured in male wild-type KK (white bars,  $n=5$ ) and Angptl3-deficient KK/Snk mice (gray bars,  $n=5$ ). B, The same for those measured in wild-type C57BL/6J (WT, white bars,  $n=6$ ), Angptl3-deficient congenic C57BL/6J *Angptl3<sup>hypl</sup>* (CON, gray bars,  $n=3$ ) and Angptl3-knockout mice (KO, black bars,  $n=4$ ). Blood samples were taken under ad libitum conditions. Data are the means  $\pm$  SEM. \*\*\* $P<0.001$  vs wild-type KK mice; \* $P<0.05$ , \*\* $P<0.01$  vs C57BL/6J mice. ND; not detected.

respectively; Figure 1A). Plasma TG levels were also lower in KK/Snk mice than in KK mice, as we reported previously.<sup>7</sup> To avoid the strain effect, we established angptl3-deficient congenic C57BL/6J *Angptl3<sup>hypl</sup>* mice.<sup>14</sup> However, *Angptl3<sup>hypl</sup>* mice showed a faint expression of angptl3 in liver.<sup>8</sup> To completely eliminate the expression of angptl3, we also generated Angptl3-knockout mice, whose backstrain was C57BL/6J.<sup>15</sup> Plasma Angptl3 in both congenic C57BL/6J *Angptl3<sup>hypl</sup>* mice (CON,  $n=3$ ) and Angptl3-knockout mice (KO,  $n=4$ ) could not be detected with ELISA for mouse Angptl3, whereas its concentration was measurable in wild-type C57BL/6J mice (WT,  $n=6$ ) (WT;  $5.5 \pm 0.6$  ng/mL versus CON and KO; not detected,  $P<0.05$ ). In congenic C57BL/6J *Angptl3<sup>hypl</sup>* mice and Angptl3-knockout mice, plasma levels of HDL cholesterol and HDL-PL, as well as TG, were significantly lower compared with C57BL/6J mice; HDL cholesterol,

WT;  $60 \pm 1.3$  versus CON;  $47 \pm 2.5$  mg/dL,  $P<0.05$  or versus KO;  $30 \pm 1.8$  mg/dL,  $P<0.001$ ; HDL-PL, WT;  $137 \pm 7.6$  versus CON;  $96 \pm 6.1$  mg/dL,  $P<0.001$  or versus KO;  $66 \pm 5.2$  mg/dL,  $P<0.001$ ; TG, WT;  $13 \pm 1$  mg/dL versus CON;  $59 \pm 9$  mg/dL,  $P<0.05$  or versus KO;  $29 \pm 0.8$  mg/dL,  $P<0.01$  (Figure 1B). These results suggested that lack of Angptl3 is associated with low plasma HDL cholesterol and HDL-PL concentrations.

### ANGPTL3 Increased Plasma HDL Lipids in Angptl3-Deficient Mice

Next, we treated congenic C57BL/6J *Angptl3<sup>hypl</sup>* mice with adenovirus expressing lacZ or human ANGPTL3. Plasma HDL cholesterol concentrations increased from day 4 ( $48 \pm 1.8$  versus  $32 \pm 1.3$  mg/dL,  $P<0.001$ ) and doubled on day 10 ( $69 \pm 3.0$  versus  $33 \pm 2.6$  mg/dL,  $P<0.001$ ) after treatment with adenovirus producing ANGPTL3, compared with the control (Figure 2A). Plasma HDL-PL levels were also increased from day 4 and doubled on day 7 ( $399 \pm 5.6$  versus  $216 \pm 23$  mg/dL,  $P<0.001$ ) by the ANGPTL3 adenovirus, compared with the control (Figure 2A). We also analyzed lipoprotein profiles of the pooled plasma collected from adenovirus-treated congenic C57BL/6J *Angptl3<sup>hypl</sup>* mice on day 14 after adenoviral injection, with high-resolution HPLC. Cholesterol and PL concentrations increased mainly in the HDL fraction of the mice treated with ANGPTL3 adenovirus, compared with the control (Figure 2B). On the other hand, ANGPTL3 adenovirus increased only the VLDL fraction of TG (Figure 2B), a finding consistent with our previous reports.<sup>8,10</sup> These results suggest that ANGPTL3 does not only influence VLDL hydrolysis but also homeostasis of the HDL metabolism.

### ANGPTL3 Inhibited EL Activity In Vitro

Next, we investigated whether EL might be a novel target of ANGPTL3, accounting for the association between ANGPTL3 and HDL levels in plasma. Both in vitro assays, using phosphatidylcholine (Figure 3A) and human HDL particles (Figure 3B) as substrates, revealed that recombinant ANGPTL3 protein markedly inhibited the activity of EL in a dose-dependent manner. HDL particles did not inhibit phospholipase activities of EL by themselves (data not shown). To determine the domain of ANGPTL3 responsible for inactivation of EL, we produced truncated and/or mutated ANGPTL3 proteins, as shown in Figure 3C.<sup>8</sup> The N-terminal coiled-coiled region of ANGPTL3 (ANGPTL3-CC) protein suppressed EL activity in a manner similar to that by full-length ANGPTL3 protein (Figure 3C). This inhibitory effect was completely abolished when the region of the heparin-binding site was mutated (Figure 3C), suggesting that the putative heparin-binding site in the N-terminal region is important for ANGPTL3-induced suppression of EL activity.

### Heparin-Releasable Phospholipase Activity Was Elevated in Angptl3-Deficient Mice

EL is responsible for the bulk of heparin-releasable phospholipase activity in mice.<sup>7</sup> To investigate whether Angptl3-deficiency leads to the elevation of EL activity in blood vessels, we measured the enzymatic activities of phospho-